Hutchison China Meditech Begins New Study For Epitinib Treatment

6th Mar 2018 09:44

LONDON (Alliance News) - Pharmaceutical firm Hutchison China Meditech Ltd has started a phase Ib/II proof-of-concept study for its proposed brain cancer treatment epitinib.

Epitinib is being trialled in patients with glioblastoma with epidermal growth factor receptor gene amplification in China, Hutchison said.

The treatment, taken orally, is an EGFR inhibitor which the company said has shown penetration of the blood-brain barrier and encouraging efficacy in other clinical studies for other indications.

Shares were up 1.0% on Tuesday at 4,925.00 pence each.

---

Related Shares:

Hutchmed